



Harold J. Olney, MD, FRCPC Montreal, September 2017

Declaration of potential conflit of interests

 Have received honorarium as advisor and/or speaker for :

Amgen

Bristol Myers Squibb

Celgene

Novartis

Paladin Laboratories






Lymphomas

- Group of cancers that originate in the lymphatic system (bone marrow, lymph nodes and other lymphoid organs such spleen and thymus)
 - A network of drainage vessels paralleling blood vessels
 - Bean shaped glands (lymph nodes)
 - This system of vessels ultimately meets and drains into the blood vessels in the neck
- Lymph vessels transport:
 - A normally clear liquid (lymph)
 - Lymphocytes, cells primarilly fighting infections





The Lymphatic System




@ MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED.





Anatomy of a lymph node









Lymphocytes

- B-cells develop in the bone marrow and key players of the immune system.
 - Produce antibodies, a protein, that circulates in blood and other body fluids capable of specifically targeting different structures on cells (infected or cancerous), microbes, other proteins (e.g. hormones)
- T-cells develop and mature in the thymus gland. Killer Tcells destroy virus infected cells and cancers. Helper T-cells orchestrate an immune response.
- NK (natural killer) cells destroy virus infected cells and cancers non specifically without delay. Can gain specificity by using antibodies that are produced by the B lymphocyte.














Causes of lymphoma

- For the majority of cases, there is no known cause and no pre-existing risk factor
- Predisposition has been seen with:
 - Congenital immunodeficiencies;
 - Immunosuppression (e.g. HIV, post transplantation);
 - Auto-immune disorders;
 - Prior chemotherapy or radiation therapy;
 - Exposition to certain pesticides;
 - Alterations in lymphocytes following certain viral infections





Lymphoma in Canada



- 5th most common cancer
- In 2017 (estimates):
 - ~ 12 190 new cases* (Cf. ~ 206 200 total)
 - ~ 3590 deaths* (Cf. ~80 800 total)
 - Slight male predisposition (~ 55% of cases)
- NHL deaths have declined in \circlearrowleft by 2,3%/yr & in \hookrightarrow by 2,5%/yr during 2000 to 2012


 * Includes CLL representing * 47% new leukemia cases and $^{\sim}$ 26% of leukemia deaths in Canada

Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2017





Increasing age is a risk factor for NHL







Lymphoma Types

Lymphoma

Hodgkin

- 1,000 patients diagnosed each year
- Relative 5-year survival 85%
- Leading cancer age
 15-29

Non-Hodgkin

- 8,200 new cases NHL each year
- Relative 5-year survival 66% but varies greatly by subtype

Chronic lymphocytic leukemia

- 2,200 patients diagnosed this year
- 7-10 year survival for most





Lymphomas can present with many different clinical manifestations.

- Variable
 - Severity: asymptomatic to extremely ill
 - Time course: evolution over weeks, months, or years
- Systemic manifestations
 - fever, night sweats, weight loss, anorexia, pruritis
- Local manifestations
 - lymphadenopathy, splenomegaly most common
 - any tissue potentially can be infiltrated





Lymphomas don't just arise in lymph nodes.

Nodal Sites <u>Extranodal</u>

Neck GI tract (stomach)

Supraclavicular Bone

Axillary Liver

Groin Skin

Spleen Head and neck

Bone marrow





Other Complications of Lymphoma

- Bone marrow failure (low blood counts)
- CNS infiltration
- Immune hemolysis or thrombocytopenia
- Compression of adjacent structures (e.g. spinal cord, ureters) by bulky disease
- Pleural/pericardial effusions, ascites





Diagnosis of Lymphoma

- History:
 - Unwell non specifically (or not)
 - Lumps/bumps
 - Short of breath, abdominal pain/symptoms
 - B symptoms:
 - Fever
 - Drenching Night Sweats
 - Weight loss (>10% of baseline weight)





Classifying lymphomas by their clinical behaviour

Indolent NHL or CLL

- Slow growth
- Often asymptomatic
- Long natural history possible
- Incurable with standard therapy

Aggressive NHL or HL


- Rapid growth
- Often symptomatic
- Fatal in months (if untreated)
- Potential for cure with standard therapy






Lymphoma Classification


Morphology




Immunohistochemistry



Cytogenetics



(gene expression profiling)







Current Lymphoma Classification WHO – 2016 Revision

There are over 60 types of lymphoma.

Hodgkin lymphoma

Classical Hodgkin lymphomas (4)

Nodular lymphocyte predominant Hodgkin lymphoma (1)

Mature B-cell neoplasms (41 types)

Mature T-cell & NK-cell neoplasms (27 types)





Hodgkin Lymphoma

Classical Hodgkin Lymphoma

Nodular sclerosis classic Hodgkin lymphoma Lmphocyte-rich classical Hodgkin lymphoma Mixed-cellularity classical Hodgkin lymphoma Lymphocyte-depleted classical Hodgkin Lymphoma

Non-classical Hodgkin lymphoma

Nodular lymphocyte-predominant Hodgkin lymphoma (low grade with watch and wait)





B cell Non Hodgkin

Chronic lymphocytic leukemia/small lymphocytic lymphoma

Monoclonal B-cell lymphocytosis*

B-cell prolymphocytic leukemia

Splenic marginal zone lymphoma

Hairy cell leukemia

Splenic B-cell lymphoma/leukemia, unclassifiable

Splenic diffuse red pulp small B-cell lymphoma

Hairy cell leukemia-variant

Lymphoplasmacytic lymphoma

Waldenström macroglobulinemia

Monoclonal gammopathy of undetermined significance (MGUS),

IgM*

μ heavy-chain disease

γ heavy-chain disease

α heavy-chain disease

Monoclonal gammopathy of undetermined significance (MGUS),

IgG/A*

Plasma cell myeloma

Solitary plasmacytoma of bone

Extraosseous plasmacytoma

Monoclonal immunoglobulin deposition diseases*

Extranodal marginal zone lymphoma of mucosa-associated

lymphoid tissue (MALT lymphoma)

Nodal marginal zone lymphoma

Pediatric nodal marginal zone lymphoma

Follicular lymphoma

In situ follicular neoplasia*

Duodenal-type follicular lymphoma*

Pediatric-type follicular lymphoma*

Large B-cell lymphoma with IRF4 rearrangement*

Primary cutaneous follicle center lymphoma

Mantle cell lymphoma

In situ mantle cell neoplasia*

Diffuse large B-cell lymphoma (DLBCL), NOS

Germinal center B-cell type*

Activated B-cell type*

T-cell/histiocyte-rich large B-cell lymphoma

Primary DLBCL of the central nervous system (CNS)

Primary cutaneous DLBCL, leg type

EBV+ DLBCL, NOS*

EBV+ mucocutaneous ulcer*

DLBCL associated with chronic inflammation

Lymphomatoid granulomatosis

Primary mediastinal (thymic) large B-cell lymphoma

Intravascular large B-cell lymphoma

ALK+ large B-cell lymphoma

Plasmablastic lymphoma

Primary effusion lymphoma

HHV8+ DLBCL, NOS*

Burkitt lymphoma

Burkitt-like lymphoma with 11q aberration*

High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6

rearrangements*

High-grade B-cell lymphoma, NOS*

B-cell lymphoma, unclassifiable, with features intermediate between

DLBCL and classical Hodgkin lymphoma





T cell Non Hodgkin

T-cell prolymphocytic leukemia

T-cell large granular lymphocytic leukemia

Chronic lymphoproliferative disorder of NK cells

Aggressive NK-cell leukemia

Systemic EBV+ T-cell lymphoma of childhood*

Hydroa vacciniforme-like lymphoproliferative disorder*

Adult T-cell leukemia/lymphoma

Extranodal NK-/T-cell lymphoma, nasal type

Enteropathy-associated T-cell lymphoma

Monomorphic epitheliotropic intestinal T-cell lymphoma*

Indolent T-cell lymphoproliferative disorder of the GI tract*

Hepatosplenic T-cell lymphoma

Subcutaneous panniculitis-like T-cell lymphoma

Mycosis fungoides

Sézary syndrome

Primary cutaneous CD30+ T-cell lymphoproliferative disorders

Lymphomatoid papulosis

Primary cutaneous anaplastic large cell lymphoma

Primary cutaneous γδ T-cell lymphoma

Primary cutaneous CD8+ aggressive epidermotropic

cytotoxic T-cell lymphoma

Primary cutaneous acral CD8+ T-cell lymphoma*

Primary cutaneous CD4+ small/medium T-cell

lymphoproliferative disorder*

Peripheral T-cell lymphoma, NOS

Angioimmunoblastic T-cell lymphoma

Follicular T-cell lymphoma*

Nodal peripheral T-cell lymphoma with TFH phenotype*

Anaplastic large-cell lymphoma, ALK+


Anaplastic large-cell lymphoma, ALK-*

Breast implant-associated anaplastic large-cell lymphoma*






Non Hodgkin Lymphoma





The different lymphomas originate at different levels of lymphocyte maturation.

B Cell Cancers by Cell Development







Lymphoma: How do we figure out what type you have?

Physical Exam

- Cardiac, respiratory, abdominal,
- Lymph nodes

Biopsy

- FNA
- Incisional biopsy
- Excisional biopsy

Laboratory:

- CBC and differential
- LDH (prognostic marker in NHL)
- ESR (important in HD)
- Bone marrow aspirate/biopsy

Imaging:

- Chest X-ray
- Ultrasound
- CT scan neck/ chest/ abdomen/pelvis
- Gallium Scan
- PET


Other:

 LP – if CNS symptoms, or in certain high risk cases of aggressive lymphoma (sinus, testicle, bone marrow)






Pathology remains the absolute most critical piece of the diagnostic workup....








Biopsies are Examined to Classify the Lymphoma









Lymphoma Stages

Stage I One lymph node region or a single organ.





Stage II
Two or more
lymph node
regions on the
same side of
the diaphragm.



Stage III

Two or more lymph node regions above and below the diaphragm.

Diaphragm



Stage IV

Widespread disease in lymph nodes and/or other parts of the body.



Designation	Characteristic
A:	Have no constitutional ('B') symptoms
В:	Have constitutional (fever, weight loss, night sweats) symptoms
E:	Involvement of areas other than lymph nodes
5:	Spleen involvement
X	Bulky disease





CLL staging system – Rai classification

Rai Stage	Risk	lymphocytes	RBC	Platelets	Lymph nodes enlarged?	Spleen enlarged?
0	Low	High	Normal	Normal	No	No
1	Intermediate	High	Normal	Normal	Yes	No
2	Intermediate	High	Normal	Normal	Maybe	Yes
3	High	High	Low	Normal	Maybe	Maybe
4	High	High	Low	Low	Maybe	Maybe






With all of the information formulation of treatment plan and prognosis.

Initial Evaluation:

Specific Histologic Sub-type
Extent of disease
General health status of patient



Treatment Plan Prognosis





The importance of classification

- There is more than one treatment for each lymphoma
- The subtype of lymphoma dictates the thrapeutic approach
- Treatment is tailored to each patient
- Statistics are useful to predict the results for a group
- It is impossible to predict the results for a specific person accurately





Category		Survival of untreated patients	Curability	To treat or not to treat
Non- Hodgkin lymphoma	Indolent	Years	Generally not curable	Generally defer Rx if asymptomatic
	Aggressive	Months	Curable	Treat at Dx
	Very aggressive	Weeks	Curable	Treat at DX
Hodgkin lymphoma	All types	Variable – months to years	Curable	Treat at Dx





- Many lymphoma subtypes with different treatments and different outcomes.
- It is important you know exactly what your diagnosis is.
- If you don't know, ask your doctor.





Thank you for your attention





